Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Wolters Kluwer    WKL   NL0000395903


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

WOLTERS KLUWER : > Incentives Help in Treating Addictions during Pregnancy, Reports Addictive Disorders & Their Treatment

share with twitter share with LinkedIn share with facebook
08/31/2012 | 09:10am EDT

Philadelphia, PA (August 30, 2012) - A "contingency management" approach-offering incentives for negative drug tests-can help promote drug abstinence among pregnant women with heroin or cocaine addiction, reports a study in the September Addictive Disorders & Their Treatment.  The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contingency management (CM) works just as well whether the incentives are increased (escalating) or fixed over time, the study finds.  Incentives may also be useful in promoting other healthy behaviors during pregnancy, such as quitting smoking.  "These results further the scientific knowledge regarding CM treatment in opioid-dependent pregnant women by supporting the finding that the escalating and fixed CM schedules produce similar amounts of drug negatives urine samples early in treatment," according to the new research by Hendrée E. Jones, PhD, and colleagues of The Johns Hopkins University School of Medicine, Baltimore.

Whether Fixed or Increasing, Incentives Promote Drug Abstinence
The researchers evaluated two approaches to contingency management in pregnant women being treated for addiction to opioids (heroin and related drugs) or cocaine.  Especially combined with poverty and mental health issues, cocaine and/or heroin abuse during pregnancy can lead to adverse health outcomes for both mother and child.

The study included 90 opioid-addicted women being treated at the Center for Addiction and Pregnancy in Baltimore.  Two-thirds of the women were randomly assigned to contingency management.  In the contingency management approach, patients receive incentives in the form of vouchers as a "reward" for achieving desired outcomes-in this case, negative urine tests showing abstinence from drugs.

One group received escalating incentives, with increasing rewards for each negative urine test.  The other group received fixed incentives-the same reward for each negative test.  Previous research has shown that incentives can quickly increase rates of targeted behavior in patients with substance abuse problems.

The vouchers could be exchanged for merchandise or gift certificates.  In the escalating group, the vouchers had a starting value of $7.50, which increased by $1 per sample day (MWF) as long as the tests remained negative.  In the fixed group, the vouchers were worth $25 for each negative urine test.

Both incentive programs continued for thirteen weeks.  All women received other standard counseling and treatment, including methadone replacement therapy for heroin addiction.

All measures of opioid and heroin dependence were similar in the two contingency management groups.  With 14 opportunities to provide urine samples, the average number of negative test results was 8.1 in the escalating incentive group and 7.4 in the fixed incentive group.

There was a tendency toward higher cocaine abstinence rates among women receiving escalating incentives.  However, after five weeks there was no significant difference between groups.

Added to previous studies, the new results strengthen the evidence that providing incentives for staying drug-free is a useful part of the treatment strategy for pregnant women with opioid dependency.  The researchers believe contingency management may be especially valuable in pregnant women-to quickly reduce drug exposure to the developing fetus, and to help in meeting the goal of having both the mother and baby be drug-free at delivery.

Other reports have suggested promising effects of incentive programs in reducing smoking among pregnant women with substance use disorders.  "One recent study found that voucher reinforcement for smoking reductions  during pregnancy had a significant impact on the  smoking reduction and abstinence rates in this vulnerable population," comments coauthor Michelle Tuten, LCSW-C.  "These interventions appear to have a clinically meaningful impact on birth outcomes as well, although larger studies are needed to more fully explore birth outcome differences."  Professor Tuten is conducting further research on contingency management to reduce exposure to maternal smoking.

For her work in developing behavioral and drug treatments for substance abuse in pregnant and parenting women, Dr Jones has been selected to receive the 2012 Association for Medical Education and Research in Substance Abuse (AMERSA) Betty Ford Award.  The award will be presented during this year's AMERSA national conference on November 1 in Bethesda, Md., where Dr Jones will discuss new research affecting the clinical management of opioid dependence during pregnancy.

About Addictive Disorders & Their Treatmen
Addictive Disorders & Their Treatment is a quarterly international journal devoted to practical clinical research and treatment issues related to the misuses of alcohol and licit and illicit drugs and the study and treatment of addictive disorders and their behaviors. The journal publishes broad-spectrum, patient-oriented coverage of all aspects of addiction, directed toward an audience of psychiatrists, clinical psychologists, psychopharmacologists, and primary care practitioners

About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).

Boiler Plate Content

Robert Dekker
Vice-President, Communications
Wolters Kluwer Health
+1 (215) 521-8928


Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health
Medical Research
+1 (646) 674-6348

distributed by
share with twitter share with LinkedIn share with facebook
All news about WOLTERS KLUWER
08:40aWOLTERS KLUWER : CCH Axcess Knowledge Coach PCR eases preparation, compilation &..
04:00aWOLTERS KLUWER : Share Buyback Transaction Details August 6 – 12, 2020
08/12WOLTERS KLUWER : Sports Medicine Startup Empericus Teams up With Wolters Kluwer ..
08/12WOLTERS KLUWER : PPP Forgiveness Module Application Processing Underway
08/12WOLTERS KLUWER : CCH Axcess™ Knowledge Coach PCR eases preparation, compil..
08/12WOLTERS KLUWER : Update on Shares Held in Treasury
08/11WOLTERS KLUWER : CARES 2 legislation stalls; President Trump signs executive ord..
08/11WOLTERS KLUWER : CCH Axcess™ With Quick Start helps small accounting firms..
08/11WOLTERS KLUWER : Lien Solutions Hosts Webinar on Lender Best Practices to Manage..
08/11WOLTERS KLUWER : and Chartis to host regulatory data webinar
More news
Sales 2020 4 660 M 5 508 M 5 508 M
Net income 2020 624 M 738 M 738 M
Net Debt 2020 2 009 M 2 374 M 2 374 M
P/E ratio 2020 28,6x
Yield 2020 1,66%
Capitalization 18 689 M 22 106 M 22 090 M
EV / Sales 2020 4,44x
EV / Sales 2021 4,25x
Nbr of Employees 18 599
Free-Float 99,0%
Duration : Period :
Wolters Kluwer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WOLTERS KLUWER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 66,25 €
Last Close Price 70,54 €
Spread / Highest target 17,7%
Spread / Average Target -6,08%
Spread / Lowest Target -39,0%
EPS Revisions
Nancy McKinstry Chairman-Executive Board & Chief Executive Officer
Frans J. G. M. Cremers Chairman-Supervisory Board
Kevin B. Entricken Chief Financial Officer
Jeanette Horan Independent Member-Supervisory Board
Ann Elizabeth Ziegler Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
S&P GLOBAL INC.27.89%84 155
RELX PLC-6.77%44 770
EQUIFAX INC.19.08%20 266
TRANSUNION4.49%17 004